The next-generation surgical device from Corcym was associated with consistent durability and positive safety data. For example, freedom from structural valve deterioration was seen in 99.7% of patients.
Wearable trackers found that PE patients were more active if they underwent mechanical thrombectomy than if they were just put on anticoagulation therapy alone.
The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.
“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity.
According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025.
Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients.
